(Q24241071)

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Cisplatin-VP16 alternating with cyclophosphamide-epirubicin versus cyclophosphamide-epirubicin-vincristine in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Randomized phase II trial of high-dose 4'-epi-doxorubicin + cyclophosphamide versus high-dose 4'-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Oat cell carcinoma of the lung. A review of 138 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

7 January 2021

Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

7 January 2021

Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

7 January 2021

Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

7 January 2021

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

7 January 2021

A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

7 January 2021

Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

7 January 2021

A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

7 January 2021

Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

7 January 2021

Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

7 January 2021

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

7 January 2021

Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

7 January 2021

Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006849.PUB2

7 January 2021

10.1002/14651858.CD006849.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

18843733

1 reference

Consolidated OpenCitations Corpus – April 2017